Nestle Health Science: completes investment in Seres

Vevey / CH. (nsa) Nestle Health Science, division of Swiss Nestle S.A., has completed a 65.6 million CHF investment in Seres Health Incorporated. Based in Cambridge, Massachusetts (U.S.), Seres is a leading microbiome therapeutics company that is developing a novel class of biological drugs designed to treat diseases by restoring the function of the microbiome. The microbiome consists of around 100 trillion microorganisms that live in the body and perform a variety of functions, including supporting the immune system. This investment is aligned with Nestle´s ambition to advance the role of novel therapeutics in health care by leveraging external investment opportunities. In addition to the investment in Seres Health, Nestle Health Science has entered into a strategic innovation partnership with Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability. Flagship Ventures is also based in Cambridge, Massachusetts. For more details please visit the Nestle Health Science website.